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A REVIEW OF THE SUNSHINE ACT’S OPEN
PAYMENTS PROGRAM: ARE PATIENTS
STILL IN THE DARK?
Shirley Chen1
I.

INTRODUCTION

I

n recent years, many consumers have become more actively
involved in making socially conscientious decisions through their
consumption of products or services.2 As consumers become more
aware of the link between the goods that they buy and the practices of
businesses that provide those goods, transparency has become an
important factor in consumer decisions.3 However, consumers are not
necessarily willing to investigate further than what is reported in the
news headlines and often rely on government standards and
regulations to hold companies accountable.4 Therefore, the federal
government has been more actively involved in improving
transparency in the health care industry, given that transparency is a
helpful tool for “improving health care quality, lowering health care

1

J.D./M.B.A. Candidate, May 2015, Loyola University Chicago School of
Law and Quinlan School of Business
2
Anne Field, Consumers Like Social Responsibility—But They Aren’t Sure
What a Social Enterprise Is, FORBES, Apr. 5, 2015, available at
http://www.forbes.com/sites/annefield/2013/04/05/consumers-like-socialresponsibility-but-they-arent-sure-what-a-social-enterprise-is/;
Timothy
M.
Devinney, What is Consumer Social Responsibility?, VIMEO (Mar. 15, 2010),
https://vimeo.com/10169286.
3
Sarah LaBrecque, How Much Do Consumers Really Care About
Transparency?,
GUARDIAN,
Mar.
12,
2014,
http://www.theguardian.com/sustainable-business/transparency-consumers-carelivechat-roundup.
4
Id.
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costs, and engaging consumers in decision making about their health
care choices.”5
In particular, large pharmaceutical companies have been
increasingly scrutinized under a magnifying glass. For instance, BBC
recently published a study, which found that out of the world’s ten
largest pharmaceutical companies, nine of them spent more on sales
and marketing than they did on research and development in 2013 (in
some cases more than twice as much).6 Furthermore, most of the
pharmaceutical's marketing is directed at physicians: in 2012, while
$3 billion was spent in the United States marketing to consumers
directly, a whopping $24 billion was targeted at physicians.7
Naturally, questions have emerged regarding whether funds that
pharmaceutical companies spent on advertising and gift-giving to
physicians unduly influences the recipients’ decisions in prescribing
medications, creating a conflict of interest.8
The federal government addressed this pervasive conflict of
interest in the health care system as a result of the relationship
between physicians and pharmaceutical companies by passing the
Physician Payment Sunshine Act (Sunshine Act) as a component of

5

Ruth E. Granfors, The Open Payments Program: Enforcing Transparency
Under the Sunshine Law, in HEALTH CARE LAW ENFORCEMENT AND COMPLIANCE:
LEADING LAWYERS ON UNDERSTANDING RECENT TRENDS IN HEALTH CARE
ENFORCEMENT, UPDATING COMPLIANCE PROGRAMS, AND DEVELOPING CLIENT
STRATEGIES 23, 26 (2014 ed. 2014).
6
Richard Anderson, Pharmaceutical Industry Gets High on Fat Profits, BBC
NEWS, Nov. 6, 2014, available at http://www.bbc.com/news/business-28212223;
Ana Swanson, Big Pharmaceutical Companies Are Spending Far More on
Marketing Than Research, WASH. POST, Feb. 11, 2015, available at
http://www.washingtonpost.com/blogs/wonkblog/wp/2015/02/11/bigpharmaceutical-companies-are-spending-far-more-on-marketing-than-research/;
Gilead Sciences Doubles Its Profits to $12.1 Billion on Strength of $1,000 Per Pill
Hepatitis
Drug,
CBS,
Feb.
11,
2014,
http://sanfrancisco.cbslocal.com/2015/02/11/gilead-sciences-doubles-its-profit-in2014-to-12-1-billion-on-strength-of-1000-per-pill-hepatitis-drug/
[hereinafter
Gilead].
7
Swanson, supra note 6.
8
Shena T. Wheeler, Under the Influence: An Examination of the Tactics
Pharmaceutical Companies Use to Manipulate Physicians, 7 IND. HEALTH L. REV.
89, 90 (2010); Joshua E. Perry, et al., Trust and Transparency: Patient Perceptions
of Physicians’ Financial Relationships with Pharmaceutical Companies, 42 J.L.
MED. & ETHICS 475, 477 (Winter 2014).
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the Affordable Care Act.9 The program, officially rebranded the
Open Payments Program, was launched last fall to disclose
information on financial transactions in 2013 between physicians and
drug manufacturers.10 Specifically, the program is accessible through
the Centers for Medicare & Medicaid Services (CMS) website.11 This
article will discuss the general purpose behind the Sunshine Act, the
scope of the Open Payments Program, and finally, a review of the
program’s success and shortcomings since its launch in September
2014.
II.

BACKGROUND: THE NEED FOR TRANSPARENCY
A. An Inherent Conflict of Interest

Marketing in the pharmaceutical industry does not consist of
solely magazine advertisements, billboards, and television
commercials. Drug manufacturers exercise creative and nontraditional forms of incentive-based marketing through developing
relationships with physicians that often involve gift-giving.12 This
can include free meals or drug samples, trinkets, compensation for
speaking engagements, consulting fees, entertainment and
reimbursement for travel expenses.13 On the one hand, forming these
bonds can prove to be beneficial to the medical community as
physicians and drug manufacturers collaborate more to improve
public health and patient care.14 For example, free drug samples can
allow physicians to begin treatment early and determine whether the
drug is effective prior to a patient purchasing it.15

9

Granfors, supra note 5, at 24; see Patient Protection and Affordable Care Act,
42 U.S.C. § 1320a–7h (2010).
10
Physician Financial Transparency Reports (Sunshine Act), AM. MED.
ASS’N.,
http://www.ama-assn.org/ama/pub/advocacy/topics/sunshine-act-andphysician-financial-transparency-reports.page? (last visited Feb. 15, 2015).
11
See
Open
Payments,
CMS.GOV,
http://www.cms.gov/OpenPayments/index.html (last visited Feb. 25, 2015).
12
Wheeler, supra note 8, at 90.
13
Id. at 90–91; Perry, et al., supra note 8, at 476.
14
Perry, et al., supra note 8, at 475; BERNARD LO & MARILYN J. FIELD,
CONFLICT OF INTEREST IN MEDICAL RESEARCH, EDUCATION, AND PRACTICE 2
(2009).
15
See Lisa D. Chew, et al., A Physician Survey on the Effect of Drug Sample
Availability on Physician’s Behavior, 15 J. GEN. INTERN. MED. 478, 478 (2000).
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However, financial ties between the two parties create the risk
that physicians will be unduly influenced by large pharmaceutical
companies, compromising physicians’ objective judgment in
prescribing medication.16 In fact, studies show that gifts often have
more of an effect on physicians’ subsequent prescribing habits than
they would care to admit. For instance, those that accepted free meals
from drug companies were more likely to request that the companies’
drugs be added to a hospital formulary.17 With respect to free drug
samples, some researchers stated in their findings that drug samples
might influence physicians to dispense or prescribe drugs that
differed from their preferred drug choice.18
The risk of harm to individual patients is not the only concern
when it comes to the pharmaceutical companies’ influence over
physicians. These financially incentivized relationships may even
contribute to the overall affordability of prescription drugs when
physicians prescribe brand name drugs over equally effective generic
versions.19 For example, in the United Kingdom, it is estimated that
the National Health Service could save up to £1 billion a year by
switching from branded to generic drugs.20 By reducing the influence
that pharmaceutical companies have on physicians, there may be a
reduction in overall costs of prescription drugs across the market.
B. Pharmaceutical Practices and Profits Beg the Question
In 2013, United States pharmaceutical company, Pfizer, made
a 42% profit margin on its revenue. In early 2015, Gilead Sciences, a
pharmaceutical firm based in the Bay Area, California, announced
that it had more than doubled its revenue in 2014.21 As the
pharmaceutical industry is an integral part of the modern health care
system, the news of increased profits is consistent with the overall
trend of “pharmaceutical companies report[ing] the largest profit
margin of any industry worldwide.”22 These profits are also in line
16

Perry, et al., supra note 8, at 475.
Wheeler, supra note 8, at 105.
18
Id. at 110; Chew, supra note 15, at 482.
19
See Anderson, supra note 6.
20
Id.
21
Gilead, supra note 6.
22
Michael Callam, Who Can Afford It?: The Patient Protection and Affordable
Care Act’s Failure to Regulate Excessive Cost-Sharing of Prescription Biologic
Drugs, CLEV. ST. J. L. & HEALTH 99, 105 (2014).
17
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with the cost structure of many brand name drugs. For instance,
cancer drugs like Gleevec are among the most expensive drugs that
pharmaceutical companies have to offer with some “costing upwards
of $100,000 for a full course.”23 Some of the costs can be attributed
to patents which all eventually expire, encouraging companies to
produce as much profit as possible during the roughly ten years that
the drug is actually and exclusively on the market.24
Moreover, drug manufacturers’ marketing techniques have
likewise contributed to large profit margins and have become a point
of controversy in the past few years. For instance, Johnson &
Johnson was accused of practices in violation of federal antikickback statutes from 1999 to 2004.25 During that time period, the
“pharmacy’s annual purchase of Johnson & Johnson medications
nearly tripled to more than $280 million, from about $100 million.”26
Physicians and pharmacies were allegedly paid incentives to promote
three of the firm’s medicines while the firm promoted the drugs for
uses not approved by the Food and Drug Administration.27 Johnson
& Johnson eventually settled the cases for $2.2 billion, constituting
the third-largest settlement involving a pharmaceutical company in
the history of the United States.28
One of the United Kingdom’s giant pharmaceutical
companies, GlaxoSmithKline, has also come under fire. In May
2014, Chinese authorities accused the company of bribery to
government authorities and hospital officials to promote an asthma
drug.29 Furthermore, in the United States, the same company settled
with forty-four different states in June 2014 on allegations of illegal

23

Anderson, supra note 6.
Id.
25
Natasha Singer, Johnson & Johnson Accused of Drug Kickbacks, N.Y.
TIMES,
Jan.
15,
2010,
available
at
http://www.nytimes.com/2010/01/16/business/16drug.html?_r=0.
26
Id.
27
Id.; Johnson & Johnson Fined $2.2bn to Settle Drug Cases, BBC NEWS,
Nov. 4, 2015 [hereinafter Johnson & Johnson], available at
http://www.bbc.co.uk/news/business-24811664.
28
Johnson & Johnson, supra note 27.
29
GlaxoSmithKline to be Investigated by UK Fraud Body, BBC NEWS, May
27, 2014, available at http://www.bbc.com/news/business-27597312.
24
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promotion of its drugs, which may have related to its previous federal
government settlement in 2012 in the amount of $3 billion.30
The coverage in the media over the exorbitant profits that
pharmaceutical companies make in conjunction with the investigation
into their marketing practices reflect an overall desire for
transparency in the industry, especially in regards to their interactions
with physicians. This is precisely the goal of the Sunshine Act. In
particular, the Sunshine Act aims to “distinguish legitimate financial
relationships from improper ones” and “inform patients about the
relationships so that, as health care consumers, they might make
better-educated decisions about where to seek care and whom to
trust.”31
III.

THE PROGRAM’S SCOPE

As a whole, the program seeks to help make financial
relationships clearer by providing a central location for financial
interactions to be reported and monitored.32 Furthermore, it is meant
to discourage “dishonest influence on research, education, and
clinical decision-making.”33
Unlike other state and federal laws governing the health care
industry, the Open Payments Program depends on self-reporting
instead of relying on whistleblowers and government investigators.34
In particular, the program requires “applicable manufacturers” and
“applicable GPOs,” collectively deemed “Reporting Entities,” to
report to CMS any payment or transfers of value made to physicians
and teaching hospitals.35 Pharmaceutical companies qualifying as

30

GlaxoSmithKline in $105m (£63m) Settlement with 44 US States, BBC
NEWS, June 4, 2014, available at http://www.bbc.com/news/business-27706037;
see also Anderson, supra note 6.
31
Perry, et al., supra note 8, at 477.
32
See Fact Sheet for Physicians, CMS, 1, available at
http://www.cms.gov/Regulations-and-Guidance/Legislation/National-PhysicianPayment-Transparency-Program/Downloads/Physician-fact-sheet.pdf, (last visited
Feb. 24, 2015) [hereinafter Fact Sheet].
33
Id.
34
Perry, et al., supra note 8, at 475.
35
Fact Sheet, supra note 32, at 1; see Granfors, supra note 5, at 27–28
(discussing the particular characteristics to qualify as applicable manufacturers and
applicable GPOs).
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applicable manufacturers are required to report all payments falling
into the following categories:
consulting fees, compensation for services other than
consulting, including serving as faculty or as a speaker
at an event other than a continuing education program,
[h]onoraria, [g]ifts, [e]ntertainment, [f]ood and
beverage, [t]ravel and lodging, [e]ducation, [r]esearch,
[c]haritable contributions, [r]oyalty or [l]icense,
[c]urrent or prospective ownership or investment
interest, [c]ompensation for serving as faculty or as a
speaker for an unaccredited and non-certified
continuing education program, [c]ompensation for
serving as faculty or as a speaker for an accredited or
certified continuing education program, [g]rants, [and]
[s]pace rental or facility fees (teaching hospital
only).36
Physicians, on the other hand, are not required to disclose any
information to CMS.37 However, they are encouraged to register on
the site, given that the success of the program is arguably dependent
on the participation of physicians to keep records of all transfers of
value and verify the accuracy of reported information.38 Prior to
publicly revealing the information, physicians have the opportunity to
dispute any inaccurate information.39
VI.

CONCLUSION: THE RESULTS ARE IN

Reminiscent of the botched launch of the Healthcare.gov website in
the fall of 2013,40 the Open Payments Program likewise experienced
some technological difficulties leading up to the September 30, 2014
36

Fact Sheet, supra note 32, at 3.
Id. at 1–2; Granfors, supra note 5, at 34.
38
Fact Sheet, supra note 32, at 2.
39
Granfors, supra note 5, at 34.
40
See Paul Ford, The Obamacare Website Didn’t Have to Fail. How to Do
Better Next Time, BLOOMBERG BUSINESS, Oct. 16, 2013, available at
http://www.bloomberg.com/bw/articles/2013-10-16/open-source-everything-themoral-of-the-healthcare-dot-gov-debacle; see also Christi Parsons & Noam Levey,
Obama on Healthcare Sign-up Glitches: ‘It’s going to get fixed’, LA TIMES,
October
21,
2013,
available
at
http://www.latimes.com/nation/politics/politicsnow/la-obama-healthcareobamacare-signup-fix-20131021-story.html.
37
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release date. The physician registration process was lengthy and
complex; physicians that were able to register had problems
navigating the portal, and the site was even taken offline for about a
week and a half at the beginning of August.41 By the end of August,
one month prior to the launch, physicians who had completed
registration with the system had less than two weeks to review and
dispute data reported regarding their financial interactions with the
Reporting Entities. Nearly 62% of those registered found
inaccuracies.42
When the site went public at the end of September, nearly
300,000 records were withheld because they had not been verified.43
In addition, 40% of reported payments had problems with the data
and were subsequently stripped.44 Since the public unveiling of the
website, the Open Payments Program continues to suffer from errors
including: misspelling, recording of payments for a single drug under
multiple names, and payments recorded without connecting them to
specific products.45 In addition, some subsidiaries recorded payments
made by its parent company for the same drugs.46 These mishaps
make it difficult for patients to get a true sense of the financial
relationships.47 According to CMS, most of the reporting errors are
on the part of Reporting Entities, and CMS is committed to not

41

Troubles with Sunshine Act Website? We’re Taking Them to CMS, AMA
WIRE, Aug. 13, 2014, available at http://www.ama-assn.org/ama/pub/amawire/ama-wire/post/troubles-sunshine-act-website-were-taking-cms (last visited
Jan. 28, 2015).
42
Time Running Out to Review Sunshine Data—And It Isn’t Very Accurate,
AMA WIRE, Aug. 28, 2014, available at http://www.ama-assn.org/ama/pub/amawire/ama-wire/post/time-running-out-review-sunshine-data-isnt-very-accurate (last
visited Jan. 28, 2015).
43
Jason Millman, John Oliver Attacked Big Pharma Last Night. Here’s One
Important Thing He Left Out., WASH. POST, Feb. 9, 2015, available at
http://www.washingtonpost.com/blogs/wonkblog/wp/2015/02/09/john-oliverattacked-big-pharma-last-night-heres-one-important-thing-he-left-out/.
44
Id.
45
Katie Wike, Open Payments Continue to be Problematic, HEALTH IT
OUTCOMES, Feb. 4, 2015, available at http://www.healthitoutcomes.com/doc/openpayments-continue-to-be-problematic-0001.
46
Id.
47
Charles Ornstein, et al., Data on Payments from Drugmakers to Doctors is
Marred by Error, N.Y. TIMES, Jan. 22, 2015, available at
http://www.nytimes.com/2015/01/23/upshot/data-on-payments-from-drugmakersto-doctors-is-marred-by-error.html?abt=0002&abg=1.
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altering any of the data provided.48 However, because the
pharmaceutical industry faced tight deadlines, and given the fact that
this is the first year that companies experimented with public
disclosure on such a scale, the accuracy of the information is
expected to improve in future years.49
Furthermore, notwithstanding the technological complications
and the reporting system’s complexity, to what degree has the Open
Payments Program been effective on perceptions? Since the launch in
September 2014, a market research firm surveyed 461 physicians to
determine their participation in the program in February 2015.50 Of
the total number of physicians surveyed, a little over half were either
familiar or somewhat familiar with the Sunshine Act itself, which
created the database program.51 Moreover, 46% of those surveyed
visited the CMS website to either check it out or verify the accuracy
of the reported information.52 Of that 46%, 54% stated that they did
not find any issues with the information reported despite the fact that
they believed some activities that should have been reported were
not.53 Of the 54% that did not visit the site, a little over half did not
care if any payments had been reported.54
Overall, 76% of physicians participating in the survey
believed that their activities with the pharmaceutical company had
not changed since the launch of the program and the disclosure of
their 2013 activities.55 This is, however, no indication of the future
success of the program. For instance, 21% of participants did report a
decrease in activity.56 And although the Open Payments Program
began with a rocky start, there is still hope in the program to achieve
its original goals of bringing transparency in the health care industry
to consumers and patients. As the program develops and participating
entities begin learning to effectively and accurately report
48

Id.
Id.
50
Ed Silverman, What Money? Many Docs Haven’t Visited the Open
Payments Database, WALL STREET JOURNAL, Feb. 20, 2015, available at
http://blogs.wsj.com/pharmalot/2015/02/20/what-money-most-docs-havent-visitedthe-open-payments-database/.
51
Id.
52
Id.
53
Id.
54
Id.
55
Id.
56
Id.
49
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transactions, consumers will have the tools to make informed
decisions regarding their health care providers and medication. In the
long run, disclosures that better characterize physician relationships
with drug manufacturers may discourage unfair marketing practices
and ultimately reduce the price of prescription drugs across industry.

